- Loxo Oncology Inc (NASDAQ: LOXO) shares climbed 46.7 percent to $71.84 following the announcement of a 76 percent-confirmed objective response rate for the trial of Larotrectinib for the treatment for multiple forms of cancer. Citigroup upgraded Loxo Oncology from Neutral to Buy.
June 05, 2017 at 09:52PM
from Lisa Levin
No comments:
Post a Comment